| Catalog No. | HX126016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Chimeric |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Claudin-18, CLDN18 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P56856 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | Claudin18.2, GC-182, IMAB-362, IMAB362, Claudiximab, 1496553-00-4 |
|---|
| Background | HY-P990946 is an CLDN18-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
• Claudin 18.2 as a novel therapeutic target., PMID:38503878
• Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?, PMID:38339430
• Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach., PMID:39098518
• Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial., PMID:37524953
• Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development., PMID:19047087
• Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer., PMID:36610262
• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial., PMID:37068504
• Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression., PMID:38200591
• Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody., PMID:37860278
• Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer., PMID:28494772
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
